Metastatic colorectal Carcinoma
Metastatic colorectal Carcinoma is one of the most common cancer in the world, second most commonly diagnosed cancer in Europe. Approximately 25% of patients initially diagnosed with colorectal carcinoma have metastases at the time of the first diagnosis and almost 50% of the diagnosed patients develop metastases, which explains the high mortality rate of these tumors.
The carcinogenic process can be inhibited by the inactivation of EGFR receptors, making them important therapeutic targets. However, around 90-80% of patients do not respond to the EGFR targeted therapy. Resistance is mainly due to KRAS gene mutations.
HeartGenetics’ OncoAlvo® is performed using single targeted mutation analysis through the highly accurate and innovative iPLEX MassARRAY® system. OncoAlvo® provides useful information for the treatment of metastatic colorectal carcinoma.
Benefits of genetic testing
- Recommended by all major international guidelines (ASCO, ESMO, NICE)
- Actionable therapeutic decisions for diagnosed patients
- Scientifically validated and proven clinical validity
- Robust method
- FFPE tissue section
OncoAlvo® evaluates 171 genetic alterations in 6 genes:
- KRAS (65), NRAS (45), BRAF (21), EGFR (2), ERBB2 (6), PIK3CA (32)
- 99% Sensitivy
- 99% Accuracy
International Medical Guidelines
OncoAlvo® genetic test screens all mutations recommended by the ESMO, ASCO & NICE Medical Guidelines with 99% accuracy.
The guidelines from the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO) and the UK National Institute for Health and Care Excellence (NICE) state the RAS mutational status to be a negative predictive biomarker for therapeutic choices involving EGFR antibody therapies in the metastatic colorectal cancer, recommending for RAS testing before treatment with the EGFR-targeted monoclonal antibodies cetuximab and panitumumab.